Temsirolimus and Radiation for Non-Small Cell Lung Cancer
| Status: | Archived |
|---|---|
| Conditions: | Lung Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | March 2009 |
| End Date: | September 2015 |
A Phase I Study of Temsirolimus and Thoracic Radiation in Non-Small Cell Lung Cancer (NSCLC)
To determine the maximum tolerated dose of the drug temsirolimus (15mg, 20mg or 25mg) given
with radiation therapy for patients with non-small cell lung cancer.
Temsirolimus has demonstrated anti-proliferative and anti-angiogenic activity in multiple
epithelial cancers, is well-tolerated, has non-overlapping toxicities with radiation, and
has been shown to potentiate the effects of radiation in vitro. Locally advanced non-small
cell lung cancer is cured in a minority of patients with concurrent chemoradiation but newer
agents are needed. In this study temsirolimus will be studied in combination with radiation
in a phase I setting to establish safety.
We found this trial at
1
site
Washington University Washington University creates an environment to encourage and support an ethos of wide-ranging...
Click here to add this to my saved trials
